<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37470370</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1525-6049</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Renal failure</Title><ISOAbbreviation>Ren Fail</ISOAbbreviation></Journal><ArticleTitle>Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>2235431</StartPage><MedlinePgn>2235431</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2235431</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2023.2235431</ELocationID><Abstract><AbstractText><b>Purpose:</b> To investigate the clinical characteristics, pathological features, and outcomes of patients with antineutrophil cytoplasmic antibody (ANCA)-positive systemic lupus erythematosus (SLE) in northwest China.<b>Methods:</b> This retrospective study included 491 patients with SLE tested for ANCA antibodies and 171 patients with ANCA-associated vasculitis (AAV) as controls. Subgroup analysis limited to those with renal involvement, and by ANCA antibody subtype (PR3 vs MPO). To compare the proteinuria remission rates between ANCA-positive and ANCA-negative lupus nephritis (LN) groups, a logistic regression model was used for propensity score matching based on age, hemoglobin, and baseline estimated glomerular filtration rate (eGFR).<b>Results:</b> Compared to ANCA-negative SLE (<i>n</i>&#x2009;=&#x2009;442), ANCA-positive SLE (<i>n</i>&#x2009;=&#x2009;46) occur in older patients; however, these patients were younger than those with AAV (<i>n</i>&#x2009;=&#x2009;167). The eGFR of patients with ANCA-positive LN (<i>n</i>&#x2009;=&#x2009;25) was higher than that of patients having AAV with renal involvement (<i>n</i>&#x2009;=&#x2009;56) but lower than that of patients with ANCA-negative LN (<i>n</i>&#x2009;=&#x2009;163). Patients with SLE who had MPO-ANCA (<i>n</i>&#x2009;=&#x2009;16) had higher levels of serum creatinine compared to those with PR3-ANCA (<i>n</i>&#x2009;=&#x2009;30) (156.5&#x2009;&#xb5;mol/L vs. 45.5&#x2009;&#xb5;mol/L, <i>p</i>&#x2009;=&#x2009;0.005). During the follow-up period, the remission rate of proteinuria in patients with ANCA-positive LN was lower than that of patients with ANCA-negative LN (50% vs. 75%, <i>p</i>&#x2009;=&#x2009;0.008).<b>Conclusion:</b> Patients with ANCA-positive LN may have worse baseline renal function and lower protein remission rates compared to patients with ANCA-negative LN. ANCA titers should be regularly monitored throughout the follow-up period in patients with SLE, especially in cases of renal involvement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xinfang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huixian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Wanhong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Nephrology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ren Fail</MedlineTA><NlmUniqueID>8701128</NlmUniqueID><ISSNLinking>0886-022X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.11.1.7</RegistryNumber><NameOfSubstance UI="D009195">Peroxidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056648" MajorTopicYN="Y">Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009195" MajorTopicYN="N">Peroxidase</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-neutrophil cytoplasmic antibodies</Keyword><Keyword MajorTopicYN="N">clinicopathological characteristics</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>All authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>20</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>20</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37470370</ArticleId><ArticleId IdType="pmc">PMC10360989</ArticleId><ArticleId IdType="doi">10.1080/0886022X.2023.2235431</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davidson A. What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol. 2016;12(3):1&#x2013;10. doi: 10.1038/nrrheum.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.159</ArticleId><ArticleId IdType="pmc">PMC4820834</ArticleId><ArticleId IdType="pubmed">26581344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Wilkman AS, Falk RJ.. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol. 1989;135(5):921&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880110</ArticleId><ArticleId IdType="pubmed">2683800</ArticleId></ArticleIdList></Reference><Reference><Citation>Windpessl M, Bettac EL, Gauckler P, et al. . ANCA status or clinical phenotype - What counts more? Curr Rheumatol Rep. 2021;23(6):37. doi: 10.1007/s11926-021-01002-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01002-0</ArticleId><ArticleId IdType="pmc">PMC8081707</ArticleId><ArticleId IdType="pubmed">33909191</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen D, Isenberg DA.. Antineutrophil cytoplasmic auto&#xad;antibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651&#x2013;658. doi: 10.1191/0961203303lu456rr.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu456rr</ArticleId><ArticleId IdType="pubmed">14514126</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin HJ, Ahn C, Lim CS, et al. . Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol. 2000;20(1):57&#x2013;63. doi: 10.1159/000013557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000013557</ArticleId><ArticleId IdType="pubmed">10644870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill GS, Delahousse M, Nochy D, et al. . Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005;68(5):2288&#x2013;2297. doi: 10.1111/j.1523-1755.2005.00688.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2005.00688.x</ArticleId><ArticleId IdType="pubmed">16221231</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhou M-L, Liang D-D, et al. . Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. BMJ Open. 2017;7(7):e015668. doi: 10.1136/bmjopen-2016-015668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-015668</ArticleId><ArticleId IdType="pmc">PMC5642651</ArticleId><ArticleId IdType="pubmed">28756384</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr SH, D&#x2019;Agati VD, Park H-R, et al. . Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol. 2008;3(3):682&#x2013;690. doi: 10.2215/cjn.04391007.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/cjn.04391007</ArticleId><ArticleId IdType="pmc">PMC2386714</ArticleId><ArticleId IdType="pubmed">18287252</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H-F, Fang X-H, Wu G-C, et al. . Anti-neutrophil &#xad;cytoplasmic antibodies in new-onset systemic lupus &#xad;erythematosus and lupus nephritis. Inflammation. 2008;31(4):260&#x2013;265. doi: 10.1007/s10753-008-9073-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-008-9073-3</ArticleId><ArticleId IdType="pubmed">18528749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of &#xad;rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bossuyt X, Cohen Tervaert J-W, Arimura Y, et al. . Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and &#xad;microscopic polyangiitis. Nat Rev Rheumatol. 2017;13(11):683&#x2013;692. doi: 10.1038/nrrheum.2017.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.140</ArticleId><ArticleId IdType="pubmed">28905856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1&#x2013;S276. doi: 10.1016/j.kint.2021.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Falk RJ, Andrassy K, et al. . Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187&#x2013;192. doi: 10.1002/art.1780370206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780370206</ArticleId><ArticleId IdType="pubmed">8129773</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604&#x2013;612. doi: 10.7326/0003-4819-150-9-200905050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbet SM, Lewis EJ, Schwartz MM, et al. . Factors predictive of outcome in severe lupus nephritis. Lupus nephritis collaborative study group. Am J Kidney Dis. 2000;35(5):904&#x2013;914. doi: 10.1016/s0272-6386(00)70262-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0272-6386(00)70262-9</ArticleId><ArticleId IdType="pubmed">10793026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S, Haas M, Markowitz GS, et al. . Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol. 2016;27(5):1278&#x2013;1287. doi: 10.1681/ASN.2015060612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2015060612</ArticleId><ArticleId IdType="pmc">PMC4849835</ArticleId><ArticleId IdType="pubmed">26567243</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol. 2011;7(12):691&#x2013;699. doi: 10.1038/nrrheum.2011.132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2011.132</ArticleId><ArticleId IdType="pmc">PMC3243068</ArticleId><ArticleId IdType="pubmed">21947176</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeazzi M, et al. . Anti-neutrophil cytoplasmic antibodies in 566 european patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European concerted action on the im&#xad;muno&#xad;genetics of SLE. Clin Exp Rheumatol. 1998;16(5):541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pubmed">9779300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamiya H, Tani K, Miyata J, et al. . Defensins- and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol Int. 2006;27(2):147&#x2013;152. doi: 10.1007/s00296-006-0173-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-006-0173-9</ArticleId><ArticleId IdType="pubmed">16900373</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajic-Veljic M, Lekic B, Nikolic M, et al. . Level and avidity of antineutrophil cytoplasmic antibodies specific to &#xad;lactoferrin are useful biomarkers in systemic lupus erythematosus. Clin Rheumatol. 2022;41(3):709&#x2013;720. doi: 10.1007/s10067-021-05926-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05926-x</ArticleId><ArticleId IdType="pubmed">34618258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Huang X, Cai J, et al. . Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: a retrospective study. Medicine (Baltimore). 2016;95(4):e2580. doi: 10.1097/MD.0000000000002580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002580</ArticleId><ArticleId IdType="pmc">PMC5291573</ArticleId><ArticleId IdType="pubmed">26825903</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Shang J, Xiao J, et al. . Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody. Ren Fail. 2020;42(1):244&#x2013;254. doi: 10.1080/0886022X.2020.1735416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2020.1735416</ArticleId><ArticleId IdType="pmc">PMC7067160</ArticleId><ArticleId IdType="pubmed">32228220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyo JY, Jung SM, Song JJ, et al. . ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis. Rheumatol Int. 2019;39(5):879&#x2013;884. doi: 10.1007/s00296-019-04263-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04263-2</ArticleId><ArticleId IdType="pubmed">30806732</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner-Stokes T, Wilson HR, Morreale M, et al. . Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int. 2017;92(5):1223&#x2013;1231. doi: 10.1016/j.kint.2017.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.04.029</ArticleId><ArticleId IdType="pmc">PMC5652376</ArticleId><ArticleId IdType="pubmed">28750930</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennette JC, Xiao H, Falk RJ.. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol. 2006;17(5):1235&#x2013;1242. doi: 10.1681/ASN.2005101048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2005101048</ArticleId><ArticleId IdType="pubmed">16624929</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates M, Watts R.. ANCA-associated vasculitis. Clin Med (Lond). 2017;17(1):60&#x2013;64. doi: 10.7861/clinmedicine.17-1-60.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.17-1-60</ArticleId><ArticleId IdType="pmc">PMC6297586</ArticleId><ArticleId IdType="pubmed">28148583</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Yu F, Zhang Y, et al. . Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore). 2008;87(4):203&#x2013;209. doi: 10.1097/MD.0b013e31817c744b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0b013e31817c744b</ArticleId><ArticleId IdType="pubmed">18626303</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wang J-J, Zhou M-L, et al. . Differences in clinico-pathological characteristics and outcomes between proteinase 3-ANCA positivity and myeloperoxidase-ANCA positivity in lupus nephritis. Lupus. 2019;28(9):1111&#x2013;1119. doi: 10.1177/0961203319861680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319861680</ArticleId><ArticleId IdType="pubmed">31291845</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper L, Savage CO.. ANCA-associated renal vasculitis at the end of the twentieth century&#x2013;a disease of older patients. Rheumatology (Oxford). 2005;44(4):495&#x2013;501. doi: 10.1093/rheumatology/keh522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh522</ArticleId><ArticleId IdType="pubmed">15613403</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Liang D, Zhang H, et al. . Long-term renal outcomes in a cohort of 1814 chinese patients with biopsy-proven lupus nephritis. Lupus. 2015;24(14):1468&#x2013;1478. doi: 10.1177/0961203315593166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315593166</ArticleId><ArticleId IdType="pubmed">26139236</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbet SM, Schwartz MM, Evans J, et al. . Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244&#x2013;254. doi: 10.1681/asn.2006090992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/asn.2006090992</ArticleId><ArticleId IdType="pubmed">17167111</ArticleId></ArticleIdList></Reference><Reference><Citation>Fussner LA, Hummel AM, Schroeder DR, et al. . Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 2016;68(7):1700&#x2013;1710. doi: 10.1002/art.39637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39637</ArticleId><ArticleId IdType="pmc">PMC7137903</ArticleId><ArticleId IdType="pubmed">26882078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>